| Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer G Zadra, CF Ribeiro, P Chetta, Y Ho, S Cacciatore, X Gao, S Syamala, ... Proceedings of the National Academy of Sciences 116 (2), 631-640, 2019 | 232 | 2019 |
| A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo C Kofink, N Trainor, B Mair, S Wöhrle, M Wurm, N Mischerikow, MJ Roy, ... Nature Communications 13 (1), 5969, 2022 | 85 | 2022 |
| ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer MM Centenera, JS Scott, J Machiels, ZD Nassar, DC Miller, I Zinonos, ... Cancer research 81 (7), 1704-1718, 2021 | 56 | 2021 |
| Molecular characterization of prostate cancer with associated Gleason score using mass spectrometry imaging EC Randall, G Zadra, P Chetta, BGC Lopez, S Syamala, SS Basu, ... Molecular Cancer Research 17 (5), 1155-1165, 2019 | 56 | 2019 |
| Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer P Chetta, G Zadra Cancer Drug Resistance 4 (1), 143, 2021 | 23 | 2021 |
| Ductal adenocarcinoma of the prostate: A systematic review and meta‐analysis of incidence, presentation, prognosis, and management N Ranasinha, A Omer, Y Philippou, E Harriss, L Davies, K Chow, ... Bjui Compass 2 (1), 13-23, 2021 | 20 | 2021 |
| Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist JM García-Martínez, S Wang, C Weishaeupl, A Wernitznig, P Chetta, ... Molecular Cancer Therapeutics 20 (1), 96-108, 2021 | 20 | 2021 |
| Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling B Wilding, D Scharn, D Böse, A Baum, V Santoro, P Chetta, R Schnitzer, ... Nature Cancer 3 (7), 821-836, 2022 | 11 | 2022 |
| Patient-derived head and neck tumor slice cultures: a versatile tool to study oncolytic virus action A Runge, M Mayr, T Schwaiger, S Sprung, P Chetta, T Gottfried, J Dudas, ... Scientific Reports 12 (1), 15334, 2022 | 7 | 2022 |
| Potent induction of a tumor-specific immune response by a cyclic dinucleotide STING agonist G Gremel, MA Impagnatiello, S Carotta, O Schaaf, PM Chetta, T Oost, ... Cancer Research 80 (16_Supplement), 4522-4522, 2020 | 6 | 2020 |
| Lactate as key metabolite in prostate cancer progression: what are the clinical implications? P Chetta, R Sriram, G Zadra Cancers 15 (13), 3473, 2023 | 5 | 2023 |
| LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager L Corrales, S Hipp, K Martin, N Sabarth, I Tirapu, K Fuchs, B Thaler, ... Frontiers in Immunology 13, 1008764, 2022 | 3 | 2022 |
| Precision RNAi using synthetic shRNAmir target sites T Hoffmann, A Hörmann, M Corcokovic, J Zmajkovic, M Hinterndorfer, ... Elife 12, RP84792, 2023 | 2 | 2023 |
| Novel EGFR WT sparing, HER2 selective inhibitors for the treatment of HER2 exon 20 insertion driven tumors address a clear unmet medical need RA Neumüller, B Wilding, D Scharn, D Böse, V Santoro, D Gerlach, ... Cancer Research 81 (13_Supplement), 1472-1472, 2021 | 1 | 2021 |
| 108P Targeting de novo lipogenesis synergizes with androgen-receptor inhibitors in castration-resistant prostate cancer PV Nuzzo, CF Ribeiro, S Rodrigues, C Sprenger, G Zadra, P Chetta, ... ESMO Open 9, 2024 | | 2024 |
| Abstract C140: BI 1810631 is a novel EGFR wild-type sparing, HER2-selective small molecule inhibitor that efficiently blocks HER2 mutant-driven lung cancer RA Neumüller, B Wilding, D Scharn, A Baum, M Augsten, I Waizenegger, ... Molecular Cancer Therapeutics 22 (12_Supplement), C140-C140, 2023 | | 2023 |
| P09. 15 Patient-derived head and neck tumor slice cultures–a versatile tool to study oncolytic virus action M Mayr, A Runge, T Schwaiger, S Sprung, P Chetta, T Gottfried, J Dudas, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 1), 2022 | | 2022 |
| BI 905711 selectively induces apoptosis and anti-tumor response in TRAILR2/CDH17-expressing pancreatic cancer models J Han, AA Machado, M Mahendra, JR Daniele, CA Bristow, JKL Huang, ... Cancer Research 81 (13_Supplement), 985-985, 2021 | | 2021 |
| Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer (vol 116, pg 631, 2018) G Zadra, CF Ribeiro, P Chetta, S Cacciatore, X Gao, S Syamala, C Bango, ... PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF …, 2020 | | 2020 |
| MP67-19 DUCTAL ADENOCARCINOMA OF THE PROSTATE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF INCIDENCE, PRESENTATION AND MANAGEMENT NMS Ranasinha*, A Omer, E Harriss, L Davies, K Chow, PM Chetta, ... The Journal of Urology 203 (Supplement 4), e1032-e1033, 2020 | | 2020 |
